Protalix BioTherapeutics (PLX) Cash & Current Investments (2010 - 2026)

Protalix BioTherapeutics has reported Cash & Current Investments for 17 years, with the latest figure at $10.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 68.93% year-over-year to $10.8 million; the trailing twelve-month figure through Mar 2026 stood at $10.8 million (down 68.93% YoY), and the FY2025 full-year result was $16.3 million, up 8.13% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $10.8 million, down from $16.3 million in the prior quarter.
• The five-year high for Cash & Current Investments was $48.5 million in Q1 2024, with the low at $10.8 million in Q1 2026.
• Average Cash & Current Investments over 5 years is $31.3 million, with a median of $32.9 million recorded in 2022.
• Year-over-year, Cash & Current Investments soared 100.9% in 2023 and sank 68.93% in 2026.
• Tracing PLX's Cash & Current Investments over 5 years: stood at $22.2 million in 2022, then soared by 100.9% to $44.6 million in 2023, then plunged by 66.18% to $15.1 million in 2024, then rose by 8.13% to $16.3 million in 2025, then slumped by 33.76% to $10.8 million in 2026.
• The last three Cash & Current Investments figures came in at $10.8 million (Q1 2026), $16.3 million (Q4 2025), and $29.4 million (Q3 2025), per Business Quant data.

Peer Comparison